Trial No: 0
Date registered: 2024-03-05
Trial Status: Pending |
|
TRIAL DESCRIPTION |
Public title |
SINGLE-CENTRE/MULTI-GROUP/OPEN/RANDOMIZED/PLACEBO-CONTROLLED 30 WEEKS PHASE I CLINICAL TRIAL OF ANCILLA DOMINI PREVENTIVE/CURATIVE FOODS ON DIABETES (II); HYPERTENSION/ CARDIAC ARRHYTHMIAS; OBESITY AN |
Official scientific title |
SINGLE-CENTRE/MULTI-GROUP/OPEN/RANDOMIZED/PLACEBO-CONTROLLED 30 WEEKS PHASE I CLINICAL TRIAL OF ANCILLA DOMINI PREVENTIVE/CURATIVE FOODS ON DIABETES (II); HYPERTENSION/ CARDIAC ARRHYTHMIAS; OBESITY AND GASTROINTESTINAL TRACT (GIT) ULCERS. |
Brief summary describing the background
and objectives of the trial |
We discovered NANO BIOTECH INVERSE TRANSCRIPTOR 1.9.90 (N-BIT1.9.90) for discovering drugs
Following a 2-decade research, we have discovered/produced permanent cure/preventions for:
HYPERTENSION
DIABETES (II)
GIT ULCERS
OBESITY NORMALIIZATION in food forms.
Our ambition is to stimulate a paradigm shift from drug-based healthcare system marred by side effects to a food-based healthcare system devoid of side effects, hence, develop an abacus for AFRICAN PHARMACOPEIA/DEVELOPMENT (APaD). |
Type of trial |
Treatment |
Acronym (If the trial has an acronym then
please provide) |
SINGLE-CENTRE/MULTI-GROUP/OPEN/RANDOMIZED/PLACEBO-CONTROLLED 30 WEEKS PHASE I CLINICAL TRIAL OF ANCILLA DOMINI PREVENTIVE/CURATIVE FOODS ON DIABETES (II); HYPERTENSION/ CARDIAC ARRHYTHMIAS; OBESITY AN |
Disease(s) or condition(s) being studied |
HYPERTENSION/CARDIAC ARRHYTHMIAS; DIABETES (II); OBESITY DECIMATION/NORMALIZATION; GASTRO-INTESTINAL TRACT ULCERS
|
Purpose of the trial |
|
Anticipated trial start date |
2024-04-15
|
Actual trial start date |
2024-04-22
|
Anticipated date of last follow up
|
2024-11-18
|
Actual date of last follow up
|
2024-11-25
|
Anticipated target sample size (number of
participants) |
100 |
Actual target sample size (number of
participants) |
35
|
Recruitment status |
Not yet recruiting
|
No |
Secondary ID |
Issuing authority/Trial register |
1 | 1 |
1 |
|